Back to Agenda
Session 3 Track 1: Clinical Development of Oligonucleotide Therapeutics for Viral and Kidney Diseases
Session Chair(s)
Laura Sepp-Lorenzino, PhD
Chief Scientific Officer
Intellia Therapeutics, Inc., United States
![Zheng Li Li, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Zheng Li Li, PhD
Pharmacologist
FDA, United States
This session will provide updates on siRNAs in clinical development for chronic hepatitis and cancer. Liver-targeted silencers of Hepatitis B Virus are being developed in combination with viral life cycle inhibitors and immune enhancing therapies, with the goal of breaking tolerance and establishing a functional cure in chronic hepatitis B patients. Phase ½ mono and combination therapy data for two HBV silencers will be presented. The last talk will highlight the clinical experience with an extra-hepatic siRNA candidate being developed for renal cell carcinoma, targeting HIF2.
Learning Objective : At the conclusion of this session, participants should be able to:
- Compare and contrast various oligonucleotide modalities and their applications
- Recognize clinical development considerations and trial designs for mono and combination therapies
- Discuss data from most advanced oligonucleotide drug/candidates for liver and kidney disease targets
Speaker(s)
![Daniel Cloutier, PharmD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Clinical Development of VIR-2218, a GalNAc-siRNA Targeting Hepatitis B, in Combination with Immune Enhancing Therapies
Daniel Cloutier, PharmD
Vir Biotechnology, Inc., United States
Senior Director, Clinical Research, Clinical Lead, HBV Program
Short Interfering RNA JNJ-3989 Combination Therapy
Michael Biermer, MD
Janssen Pharmaceuticals, Belgium
Senior Medical Director, Clinical Development
ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma Ph1b
James Hamilton Hamilton, MD, MBA
Arrowhead Pharmaceuticals, United States
Senior Vice President, Discovery and Transitional Medicine
Have an account?